MATERIALS AND METHODS

Cell lines, human samples and reagents
All human cancer cell lines (SNU-5, SNU-1, U-87MG, 786-O, A549, H441, H596, H1437, H1993, BT474, A549, HT-29) were purchased from the American Type Culture Collection (ATCC) and routinely maintained according to ATCC's recommendations.
MKN-45 cell line was obtained from German Collection of Microorganisms and Cell
Cultures and maintained according to supplier's recommendation. The S114 cell line that stably expresses human HGF and c-MET was obtained from the National Institutes of Health (Rockville, MD). Blood samples were obtained from healthy volunteers and cancer patients after informed consent was obtained in accordance with the Declaration of Helsinki and Institutional Review Board approval was received from Incyte.
INCB28060 was synthesized at Incyte Corporation as described previously (22). The compound was prepared as a 5 mM stock solution in 100% DMSO and routinely stored at room temperature. Actinomycin D and cycloheximide were purchased from SigmaAldrich.
In vitro c-MET kinase assay
The assay was performed and compound potency was determined as described previously (35) .
Western blotting
To prepare whole cell protein extracts, cells maintained in appropriate media were treated Author Manuscript Published OnlineFirst on September 14, 2011; DOI: 10.1158/1078-0432.CCR- HGF treatment was required, cells were usually starved in appropriate media containing 0.2% fetal bovine serum (FBS) for at least 24 hours and followed by pretreatment with INCB28060 for 2 hours. Cells were then stimulated with 50 ng/mL recombinant human HGF (R&D Systems) for an additional 15 minutes. Whole cell protein extracts were prepared and Western blot analysis was performed as described previously (36) agarose (Santa Cruz Biotechnology) was added to the mixture and incubate on a rotating device overnight. The pellet was collected by centrifugation at 2,500 rpm for 5 minutes and the supernatant was aspirated and discarded. The pellet was washed 4 times with lysis buffer and after the final wash, the supernatant was aspirated and discarded, and the pellet was resuspended in 20 μL of 1 x electrophoresis sample buffer. The samples were boiled for 2 minutes prior to electrophoresis. Western blot analysis was performed as described above.
Enzyme-linked immunosorbent assays (ELISAs)
ELISA-based detections of phospho-c-MET in cell protein extracts, HGF in patient plasma, and TGF-α, AR and HGR-β1 in supernatants of cultured cells were performed using respective ELISA kits from R&D systems according to the manufacturer's instructions. Prior to analyzing the samples, optimal amounts of protein extracts, human plasma or culture supernatants were determined for individual assays. The ELISA procedures were performed as following: various amounts of protein extracts, human plasma or culture supernatants were captured with a primary antibody specific for the individual protein to be measured for 2 hours in a 96-well microplate. After washes, an HRP-conjugated detection antibody (an anti-phospho-tyrosine antibody was used for phospho-c-MET detection) was added and incubated for 2 hours. After additional washes, 100 μL substrate solution was added into each well and the reaction was stopped 
Cell viability assay
Optimal cell density used in the viability assay was predetermined for individual cell lines. To determine compound potency, cells were seeded into 96-well microplates at the appropriate density in media containing 1-2 % FBS and supplemented with serial dilutions of INCB28060 in a final volume of 100 μL/well. After 72-hour incubation, 24 μL of CellTiter 96® AQueous One Solution (Promega) was added to each well, and the plates were incubated for 2 hours in a 37 o C incubator. The optical density was measured in the linear range using a microplate reader at 490 nm with wavelength correction at 650 nm. IC 50 values were calculated using the GraphPad Prism software.
Soft agar colony formation assay
U-87MG or H441 cells were prepared at adequate densities in 6-well plates mixed with 0.5 mL top layer agar containing 0.3% agarose (Cambrex) in appropriate culture medium and supplemented with 1 or 10 % FBS, in the presence or absence of 50 ng/mL recombinant human HGF and INCB28060 at various concentrations. Cells were evenly laid over 1 mL solidified base layer agar containing 0.6% agarose in culture medium.
The plates were incubated at 37 o C in a humidified incubator supplied with 5% CO 2 .
Cells were fed once a week with top agar containing appropriate concentrations of human 
Efficacy studies
Tumor bearing mice were dosed orally, twice each day with 1, 3, 10 or 30mg/kg of free base INCB028060 reconstituted in 5% DMAC in 0.5% methylcellulose for up to 2 weeks. Body weights were monitored throughout the study as a gross measure of toxicity/morbidity. Tumor growth inhibition, expressed in %, was calculated using the formula: (1-[(volume (treated)/volume (vehicle)]) x 100.
Pharmacodynamic analysis
For pharmacodynamic analysis S114 tumor bearing mice were monitored for tumor growth and then randomized into groups of 3 with average tumor sizes of approximately (Table 1) . Additional kinetic studies suggest that INCB28060 is an ATP competitive and reversible inhibitor (data not shown).
To determine the selectivity of INCB28060, the compound was profiled against a panel of 57 human kinases representing a structurally diverse cross-section of all known human kinases (Supplementary Table 1 Table   2 ). In contrast, the compound was inactive against the SNU-1 human gastric cancer cell line that does not express c-MET ( Fig. 2A and B ) and the HEK293 human embryonic kidney cell line, an immortalized non-tumorigenic cell line that expresses low levels of c-MET (Table 2) . When assessed against S114 cells, INCB28060 did inhibit cell proliferation, but with an average IC 50 value of 12.4 nM ( Table 2 ). The fact that the compound is less active against S114 cells vs. SNU-5 cells is likely due to the unusually high levels of both c-MET and HGF expressed that make S114 cells more resistant to c-MET inhibition. Collectively, the data suggest that INCB28060 exhibits potent (Fig. 2C and Table 2 ). Furthermore, PARP cleavage, a biochemical read-out for apoptotic cells, was markedly induced by INCB28060 (Fig. 2D) . A similar induction of PARP cleavage was readily detected in (Fig. 4B) , which is consistent with the compound exposure exceeding proteinadjusted IC 90 (~71 nM) for phospho-c-MET during the same period of time (Fig. 4B) . 
To determine how inhibition of c-MET phosphorylation translates to antitumor efficacy in the S114 model, tumor bearing mice were treated orally with 3, 10 or 30 mg/kg twice daily. Dose-dependent inhibition of tumor growth was seen (Fig. 4C) . Notably, complete regressions were seen in all mice in the group receiving 30 mg/kg INCB28060.
Data obtained in the more sensitive U-87MG glioblastoma model, which expresses lower levels of endogenous c-MET and HGF, showed a similar dose-dependent inhibition of tumor growth with 35% and 76% tumor growth inhibition for groups dosed with 1 and 3 mg/kg INCB28060 once daily, respectively (Fig. 4D) . Furthermore, once daily dosing of 10 mg/kg INCB28060 resulted in partial regressions in 6 out of 10 U-87MG tumor bearing mice. It is noted that in both S114 and U-87MG models, tumor growth inhibition increases with increased exposure of the compound and that tumor regressions could only be achieved when the compound exposure consistently exceeded 90% of c-MET inhibition (Fig. 4C) . In these studies, INCB28060 was well tolerated at all doses during the treatment periods, with no evidence of overt toxicity or weight loss. Taken suppressed phosphorylation of both EGFR and HER-3 rapidly and as effectively as the compound inhibited c-MET phosphorylation (Fig. 6A) . The inhibition of phosphorylated EGFR and HER-3 by INCB28060 persisted over a period of 24 hours (Fig. 6B) . Because the H1993 cell line has constitutively active c-MET as a result of c-MET amplification, addition of exogenous HGF showed little effect on the phosphorylation status of either EGFR or HER-3 with or without INCB28060 pretreatment (Fig. 6B) . Intriguingly, treatment of INCB28060 over a longer period (e.g., 24 hours) led to a dose-dependent increase in HER-3 protein levels, while EGFR protein levels were unchanged ( Fig. 6C and D) . Similar immunoprecipitation experiments performed using protein extract prepared with other human cancer cell lines showed very weak HER-3 detection after 24 hour compound treatment, likely due to low baseline HER-3 expression in those cell lines (Fig. 6D) . Collectively, the data suggest that To further assess the relevance of HGF and c-MET in cancer patients, circulating HGF levels were measured in patients with various tumor types. HGF levels were significantly higher in the majority of patients with all tumor types tested ( Supplementary Fig. 3 ).
Approximately 49% of patients showed a 2-fold or greater increase compared to healthy volunteers. The data confirms that HGF levels are frequently elevated in cancer patients and might contribute to c-MET activation. 
expression by activated c-MET might be a common mechanism because an increased level of HER-3 protein physically associated with c-MET was also noted in other cell lines treated with INCB28060, prior to immunoprecipitation with a c-MET antibody (Fig.   6D ). However, since HER-3 is expressed at fairly low levels in some tested cell lines and the HER-3 protein weakly detected by immunoprecipitation showed a slightly different size in one or two tested cell lines, further study of this issue using other model cell lines will be helpful. The fact that the induction of HER-3 protein could only be detected after 
